A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Ecleralimab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CCSJ117A12201C
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 14 Nov 2022 This trial has been completed in Czech Republic (End Date: 6 Sep 2022) according to European Clinical Trials Database record.
- 05 Oct 2022 This trial has been completed in France (End Date: 6 Sep 2022) according to European Clinical Trials Database record.
- 21 Sep 2022 This trial has been discontinued in Slovakia, according to European Clinical Trials Database record